Avenir Corporation’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.94M | Sell |
259,461
-1,328
| -0.5% | -$14K | 0.24% | 31 |
|
|
2026
Q1 | $2.95M | Sell |
260,789
-716
| -0.3% | -$9.8K | 0.36% | 26 |
|
|
2025
Q4 | $3.34M | Buy |
261,505
+7,363
| +3% | +$113K | 0.36% | 25 |
|
|
2025
Q3 | $4.75M | Buy |
254,142
+1,215
| +0.5% | +$23.9K | 0.49% | 22 |
|
|
2025
Q2 | $6.47M | Buy |
252,927
+681
| +0.3% | +$13.7K | 0.67% | 22 |
|
|
2025
Q1 | $5.04M | Buy |
252,246
+97,549
| +63% | +$2.06M | 0.53% | 23 |
|
|
2024
Q4 | $2.82M | Buy |
154,697
+5,919
| +4% | +$116K | 0.29% | 28 |
|
|
2024
Q3 | $4.46M | Buy |
148,778
+265
| +0.2% | +$5.81K | 0.45% | 23 |
|
|
2024
Q2 | $2.09M | Sell |
148,513
-10,122
| -6% | -$176K | 0.2% | 26 |
|
|
2024
Q1 | $3.01M | Buy |
158,635
+6,065
| +4% | +$118K | 0.26% | 25 |
|
|
2023
Q4 | $3.39M | Buy |
152,570
+16,700
| +12% | +$496K | 0.29% | 23 |
|
|
2023
Q3 | $5.11M | Sell |
135,870
-117
| -0.1% | -$6.72K | 0.48% | 23 |
|
|
2023
Q2 | $9.8M | Buy |
135,987
+8,209
| +6% | +$519K | 0.86% | 20 |
|
|
2023
Q1 | $8.61M | Buy |
127,778
+5,424
| +4% | +$326K | 0.81% | 20 |
|
|
2022
Q4 | $3.79M | Buy |
122,354
+6,611
| +6% | +$196K | 0.38% | 24 |
|
|
2022
Q3 | $3.15M | Buy |
115,743
+7,493
| +7% | +$293K | 0.33% | 25 |
|
|
2022
Q2 | $4.74M | Sell |
108,250
-575
| -0.5% | -$26.4K | 0.45% | 25 |
|
|
2022
Q1 | $6.94M | Buy |
108,825
+19,461
| +22% | +$1.39M | 0.55% | 25 |
|
|
2021
Q4 | $7.49M | Buy |
89,364
+19,595
| +28% | +$2.2M | 0.58% | 23 |
|
|
2021
Q3 | $11.3M | Buy |
69,769
+1,442
| +2% | +$234K | 0.95% | 22 |
|
|
2021
Q2 | $10.3M | Buy |
68,327
+50,383
| +281% | +$8.49M | 0.82% | 24 |
|
|
2021
Q1 | $3.12M | Buy |
17,944
+7,607
| +74% | +$1.45M | 0.27% | 30 |
|
|
2020
Q4 | $1.65M | Buy |
10,337
+825
| +9% | +$138K | 0.16% | 38 |
|
|
2020
Q3 | $1.52M | Buy |
9,512
+1,126
| +13% | +$203K | 0.16% | 38 |
|
|
2020
Q2 | $1.66M | Buy |
8,386
+856
| +11% | +$157K | 0.19% | 37 |
|
|
2020
Q1 | $1.16M | Hold |
7,530
| – | – | 0.16% | 41 |
|
|
2019
Q4 | $580K | Hold |
7,530
| – | – | 0.06% | 54 |
|
|
2019
Q3 | $758K | Buy |
7,530
+265
| +4% | +$30.8K | 0.08% | 52 |
|
|
2019
Q2 | $960K | Buy |
7,265
+2,903
| +67% | +$399K | 0.1% | 49 |
|
|
2019
Q1 | $660K | Buy |
4,362
+542
| +14% | +$84.4K | 0.07% | 52 |
|
|
2018
Q4 | $617K | Buy |
3,820
+1,707
| +81% | +$339K | 0.08% | 52 |
|
|
2018
Q3 | $545K | Buy |
2,113
+559
| +36% | +$140K | 0.06% | 56 |
|
|
2018
Q2 | $354K | Buy |
+1,554
| New | +$294K | 0.04% | 60 |
|
Other funds holding CTSO
CM
Avenir Corporation's CTSO Position: Q2 2026 in Review
Avenir Corporation reduced its Cytosorbents Corp (CTSO) stake by 0.51% in Q2 2026, selling an estimated $14K and leaving 259,461 shares worth $1.94M. The position accounts for 0.24% of the portfolio, ranked #31.
Avenir Corporation first reported a position in CTSO in Q2 2018 and has held it in 33 quarters since. The position peaked at $11.3M in Q3 2021. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Avenir Corporation held 259,461 shares of Cytosorbents Corp worth $1.94M as of Q2 2026.
- Avenir Corporation sold 1,328 Cytosorbents Corp shares in Q2 2026, an estimated $14K.
- Cytosorbents Corp made up 0.24% of Avenir Corporation's portfolio in Q2 2026, its #31 holding.
- Avenir Corporation first reported a position in Cytosorbents Corp in Q2 2018 and has held it in 33 quarters since.
- Avenir Corporation's Cytosorbents Corp position peaked at $11.3M in Q3 2021.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Avenir Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.